Takeda has reportedly achieved positive results in phase 3 trials for a psoriasis treatment, potentially paving the way for FDA approval. The treatment, which was acquired as part of a $4 billion deal, has shown promise in addressing difficult-to-treat cases of plaque psoriasis. The outcome of the trials may lead to a significant drug approval, although the timing and details of the approval process are not clear.